A novel biological activity of praziquantel requiring voltage-operated Ca2+ channel beta subunits: subversion of flatworm regenerative polarity.
<h4>Background</h4>Approximately 200 million people worldwide harbour parasitic flatworm infections that cause schistosomiasis. A single drug-praziquantel (PZQ)-has served as the mainstay pharmacotherapy for schistosome infections since the 1980s. However, the relevant in vivo target(s)...
Enregistré dans:
Auteurs principaux: | Taisaku Nogi, Dan Zhang, John D Chan, Jonathan S Marchant |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Public Library of Science (PLoS)
2009
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/54ba41af79114d84ae2c8babca92ef9a |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
Identification of novel modulators of a schistosome transient receptor potential channel targeted by praziquantel.
par: Evgeny G Chulkov, et autres
Publié: (2021) -
Identification of novel modulators of a schistosome transient receptor potential channel targeted by praziquantel
par: Evgeny G. Chulkov, et autres
Publié: (2021) -
Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials.
par: Dimitrios K Matthaiou, et autres
Publié: (2008) -
Metabolomics reveal alterations in arachidonic acid metabolism in Schistosoma mekongi after exposure to praziquantel.
par: Peerut Chienwichai, et autres
Publié: (2021) -
Efficacy and safety of praziquantel, tribendimidine and mebendazole in patients with co-infection of Clonorchis sinensis and other helminths.
par: Li-Li Xu, et autres
Publié: (2014)